European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“New publication alert!
We’re proud to announce the publication of the LUMEN-1 trial protocol in the The Journal of Nuclear Medicine – JNM by Nathalie Albert et al.!
The LUMEN-1 (EORTC-2334-BTG) randomised phase II trial investigates [¹⁷⁷Lu]Lu-DOTATATE for patients with recurrent meningioma, a population with limited treatment options after surgery and radiotherapy.
This is the first prospective, randomised clinical trial to evaluate the efficacy of SSTR2-targeted radionuclide therapy in this setting. The trial also includes a robust translational research programme leveraging: PET imaging and radiomics, tumour tissue profiling (genetic, epigenetic, IHC) and dosimetry and machine learning.
This work may pave the way for novel treatment strategies in neuro-oncology.”
More posts featuring European Organisation for Research and Treatment of Cancer.